Products for Research Use Only
RegisterLogin

RBN013209

CAT: 0804-HY-144987-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-144987-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
RBN013209 is an orally active small molecule inhibitor of CD38 with an IC50 of 0.01 to 0.1 μM for human CD38. RBN013209 prevents the conversion of extracellular NAD+ to ADPR or cADPR in tumor cells and PBMCs. RBN013209 can be used in the study of tumor. In addition, RBN013209 enables CAR-T cells to maintain the naive state and central memory state, and decreases the expression of cell activation markers and exhaustion-related inhibitory receptors[1][2][3].
CAS Number
2597933-17-8
UNSPSC
12352005
Target
CD38; LAG-3; PD-1/PD-L1; Tim3
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/rbn013209.html
Concentration
10mM
Purity
98.63
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
COCCO[C@@H](CC1)CC[C@H]1NC(C2=C3C(C=CN3)=NC(N4C=CN=C4)=N2)=O
Molecular Formula
C19H24N6O3
Molecular Weight
384.43
References & Citations
[1]Laurie B. Schenkel, et al. Heterobicyclic amides as inhibitors of cd38. WO2021021986A1.|[2]Shambharkar, et al. Small molecule inhibitor of CD38 modulates its intra-and extracellular functions leading to antitumor activity. Cancer Research 81.13_Supplement (2021) : 1344-1344.|[3]Huang Y, et al. Inhibition of CD38 enzymatic activity enhances CAR-T cell immune-therapeutic efficacy by repressing glycolytic metabolism. Cell Rep Med. 2024 Feb 20;5 (2) :101400.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Alternative Products

CatalogName
BA5870-25RBN013209
A24119-10RBN013209 10mg
A24119-100RBN013209 100mg
A24119-50RBN013209 50mg
A24119-5RBN013209 5mg

Popular Products